

Receptor activator of nuclear factor- κ B ligand in T cells and dendritic cells communication

Sun-Young Nam^{1,2}, Hyun-Ja Jeong^{2,*}

¹Department of Pharmacology, College of Korean Medicine, Kyung Hee University, Seoul, Republic of Korea; ²Inflammatory Disease Research Center and Biochip Research Center, Hoseo University, Asan, Chungnam, Republic of Korea

ABSTRACT

The receptor activator of NF- κ B ligand (RANKL), a member of the tumor necrosis factor ligand family, has extensive functions beyond osteoclast development. RANKL is expressed in many immune cells such as osteoblasts, osteocytes, marrow stromal cells, activated T cells, synovial cells, keratinocytes, and mammary gland epithelial cells as well as in various tissues. The ligation of RANK by RANKL promotes dendritic cells (DCs) survival through prosurvival signals and the up-regulation of the anti-apoptotic proteins Bcl-2 and Bcl-x_L and plays a crucial role in DCs-mediated Th1 differentiation. Therefore, RANKL plays an important role in the regulation of DCs/T cells-mediated specific immunity. This review will briefly inform our current understanding of the role of RANKL signaling in T cells-DCs communication in the immune system.

Keywords RANKL, dendritic cells, T cells, differentiation, immunity

INTRODUCTION

Receptor activator of nuclear factor- κ B ligand (RANKL) history

In 1981, Rodan and Martin proposed a new hypothesis that bone resorbing hormones-induced osteoblast products directly activate osteoclast formation (Rodan and Martin, 1981). The study of the osteoclast formation *in vitro* co-culture system of embryonic bone rudiments and hematopoietic cells strongly supported this hypothesis (Bruger et al., 1984). However, how osteoblasts/stromal cells activated osteoclast development was not fully understood until the osteoclast differentiation factors (ODF) were determined. Simonet et al. (1997) identified a novel member of the tumor necrosis factor receptor (TNFR) superfamily, termed osteoprotegerin (OPG). OPG was encoded by the *Tnfrsf11b* gene and a secreted protein unlike other members of the TNFR superfamily. This protein arrested osteoclast maturation *in vitro* and protected bones from normal osteoclast remodeling and ovariectomy-associated bone loss (Simon et al., 1997). At around the same time, Eisuke and coworkers at Snow Brand Milk Products Co. also purified an identical molecule, termed the osteogenesis inhibitory factor, from human embryonic lung fibroblasts (Tsuda et al., 1997). Soon, they molecularly cloned an osteoprotegerin ligand (OPGL) using OPG as a probe in 1998 (Lacey et al., 1998; Yasuda et al., 1998). OPGL was a long-sought ODF and found to be identical to the TNF-related activation-induced cytokine/RANKL, which exerts a dendritic-cell (DCs) function (Anderson et al., 1997).

RANKL

RANKL is expressed on a wide variety of different cell lineages and tissues, including osteoblasts, osteocytes, marrow

stromal cells, activated T cells, synovial cells, keratinocytes, mammary gland epithelial cells, thymus, spleen, bone marrow, heart, skeletal muscle, lung, stomach, placenta, thyroid gland, and brain (Anderson et al., 1997; Fata et al., 2000; Kartsogiannis et al., 1999; Lacey et al., 1998; Loser et al., 2000; Schett et al., 2005; Wada et al., 2006; Wong et al., 1997; Yasuda et al., 1998). Structurally, RANKL (encoded by the *Tnfsf11* gene located in human chromosome 13q14) is a type II transmembrane molecule which contains a membrane anchoring domain, a long extracellular stalk, and a receptor-binding ectodomain (Ikeda et al., 2001; Lam et al., 2001; Wong et al., 1997). The extracellular domain of RANKL self-assembles into stable homotrimers with four unique surface loops that are necessary for the engagement and activation of its signaling receptor (Ito et al., 2002; Lam et al., 2001). Intriguingly, there are three isoforms of RANKL, which is named RANKL1, RANKL2, and RANKL3. Both RANKL1 and RANKL2 are membrane-bound proteins of ~40 - 45 kDa, but RANKL2 has a shorter intracellular domain. This fact may cause the different distribution of these proteins and the functional differences. In contrast, RANKL3 lacks the intracellular or transmembrane domain and is secreted into extracellular environments as a soluble form of 31 kDa (Table 1) (Ikeda et al., 2001). Initially, RANKL is released as a membrane-bound form and sheds from the plasma membrane by the proteolytic action of TNF- α convertase which is a member of a disintegrin and metalloprotease domain family or a related metalloprotease (Lum et al., 1999). Nakashima et al. (2000) proposed that cytokines mediating osteoclastogenesis such as IL-1 β , IL-6, IL-11, IL-17, and TNF- α seem to regulate the ectodomain shedding of RANKL by the activation of metalloprotease. In osteoclastogenesis, the membrane-anchored RANKL is more effective than soluble RANKL (Nakashima et al., 2000).

Receptor activator of nuclear factor- κ B (RANK), a cognate receptor of RANKL

*Correspondence: Hyun-Ja Jeong

E-mail: hjjeong@hoseo.edu

Received December 15, 2012; Accepted February 20, 2013; Published February 28, 2013

doi: <http://dx.doi.org/10.5667/tang.2012.0047>

© 2013 by Association of Humanitas Medicine

TANG / www.e-tang.org

Table 1. Isoforms of RANKL

Isoforms	Intracellular distribution	Structure	
RANKL1	EM, Golgi networks, Cytoplasm, Membrane	 N 1 48 71 316 C	316 amino acids
RANKL2	EM, Golgi networks	 N 1 19 42 287 C	287 amino acids
RANKL3	EM, Golgi networks, Cytoplasm	 N 1 199 C	199 amino acids

EM; endoplasmic reticulum, TM; transmembrane. (Ikeda et al., 2001).

The RANK was identified as a signaling receptor for RANKL by two groups independently in the mid to late 1990s (Anderson et al., 1997; Nakagawa et al., 1998). RANK is encoded by the *Tnfrsf11a* gene located in the human chromosome 18q22.1 and a type I transmembrane protein of 616 amino acids with a extracellular domain of 184 amino acids and a cytoplasmic domain of 383 amino acids (Anderson et al., 1997). Moreover, it belongs to the TNFRs, so RANK should form trimeric complexes on cell surface prior to RANKL binding owing to signaling transduction (Francis et al., 2000). RANK is strongly expressed in skeletal muscles, bone, thymus, liver, colon, small intestine and adrenal gland and also detected in the spleen, bone marrow and several human cell lines such as K-562 (chronic myelogenous leukaemia), HFF (human foreskin fibroblasts), MP-1 (B lymphoblastoid line), A-172 (glioblastoma), and WI-26 (SV40-transformed lung fibroblast) (Anderson et al., 1997; Nakagawa et al., 1998). In addition, RANK is found to be expressed in mammary epithelial cells and several cancer cells, such as breast and prostate cancers (Chen et al., 2006; Kim et al., 2006).

RANKL in T cell–DCs communication

DCs play an important role in the regulation of specific immunities by presenting antigens to T cells. In particular, CD40, a member of TNFR family, is widely known to increase the functional activities of DCs (Caux et al., 1994). Initially, Anderson et al. isolated RANK, which has a 40% conserved extracellular domain with CD40, as a new TNFR family in DCs and also found its ligand, RANKL, by direct expression screening (Anderson et al., 1997).

RANKL is expressed on the activated CD4⁺ and CD8⁺ T cells by the T cell receptor/CD3 complex, but not on resting T cells, whereas high levels of RANK are expressed on mature DC (Wong et al., 1997). Although T and B cells slightly express RANK on their surfaces, RANKL was not able to activate T and B cells (Josien et al., 1999). The induction of RANKL in T cells is dependent on the protein kinase C, phosphoinositide 3-kinase and calcineurin-mediated signaling pathways (Kong et al., 1999). When RANKL derived from activated T cells binds to RANK on DCs, it activates intracellular tumor necrosis factor receptor-associated factor family proteins, which mediates NF- κ B and MAPK signaling pathways correlated with cell proliferation, survival and differentiation (Akiyama et al., 2012; Wong et al., 1998). Actually, Wong et al reported that RANKL was a DCs-specific survival factor, because RANKL/RANK signaling via TRAF2 increased DCs survival by upregulating Bcl-x_L expression known as an anti-apoptotic molecule and the co-stimulatory molecule CD40 on DCs (Anderson et al., 1997; Wong et al., 1997). Moreover, RANKL rearranged

CD40L/CD40-independent CD4⁺ T cell priming against to viral infections (Bachmann et al., 1999). Activated T cells express CD40L, whereas DCs express their receptors, CD40, on their surfaces. CD40L/CD40 signaling in DCs plays a crucial role in the inducing of the expressions of co-stimulatory molecules and IL-12 in DCs, which potentiate CD4⁺ T cell responses. However, it is observed that CD4⁺ T cells produced normal levels of IFN- γ in CD40L- or CD40-deficient mice upon viral infection, suggesting a CD40L/CD40-independent mechanism of CD4⁺ T cell priming. Bachmann et al. found that RANKL and RANK interaction was an additional mechanism of CD4⁺ T cell stimulation during viral infection and it was required for CD4⁺ T cell stimulation in the absence of CD40L/CD40 (Bachmann et al., 1999). This result suggests the role of RANKL in memory T cell responses. Interestingly, RANKL also regulates Th1 differentiation through the up-regulation of IL-12 in DCs. Activated DCs by RANKL produce various cytokines, including IL-12, IL-15, IL-1, and IL-6. Mice lacks CD40L, which is a critical factor involved in IL-12 production in DCs, also produced IL-2 and exerted Th1 differentiation. This result suggested that RANKL plays a crucial role in DCs-mediated Th1 differentiation. In contrast, IL-4, which is a key cytokine involved in Th2 differentiation, inhibited RANKL expression on T cells (Josien et al., 1999).

CONCLUSION

RANKL signaling in the function of immune regulatory cells, such as DCs and helper T cells might open the possibility to provide a novel molecular paradigm for disorders of the immune system.

ACKNOWLEDGEMENTS

This research was supported by Hoseo University.

CONFLICT OF INTEREST

The author has no conflicting financial interests.

REFERENCES

Akiyama T, Shinzawa M, Akiyama N. RANKL-RANK interaction in immune regulatory systems. *World J Orthop.* 2012;3:142-150.

- Anderson DM, Maraskovsky E, Billingsley WL, Dougall WC, Tometsko M E, Roux ER, Teepe MC, DuBose, RF, Cosman D, Galibert L. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. *Nature*. 1997;390:175-179.
- Boyce BF and Xing L. Biology of RANK, RANKL, and osteoprotegerin. *Arthritis Res Ther*. 2007;9:S1.
- Burger EH, van der Meer JW, Nijweide PJ. Osteoclast formation from mononuclear phagocytes: role of bone-forming cells. *J Cell Biol*. 1984;99:1901-1906.
- Caux C, Massacrier C, Vanbervliet B, Dubois B, Van Kooten C, Durand I, Banchereau J. Activation of human dendritic cells through CD40 cross-linking. *J Exp Med*. 1994;184:1263-1272.
- Chan FK, Chun HJ, Zheng L, Siegel RM, Bui KL, Lenardo MJ. A domain in TNF receptors that mediates ligand-independent receptor assembly and signaling. *Science*. 2000;288:2351-2354.
- Ikedda T, Kasai M, Utsuyama M, Hirokawa K. Determination of three isoforms of the receptor activator of nuclear factor- κ B ligand and their differential expression in bone and thymus. *Endocrinology*. 2001;142:1419-1426.
- Ito S, Wakabayashi K, Ubukata O, Hayashi S, Okada F, Hata T. Crystal structure of the extracellular domain of mouse RANK ligand at 2.2Å - resolution. *J Biol Chem*. 2002;277:6631-6636.
- Josien R, Wong BR, Li HL, Steinman RM, Choi Y. TRANCE, a TNF family member, is differentially expressed on T cell subsets and induces cytokine production in dendritic cells. *J Immunol*. 1999;162:2562-2568.
- Kartsogianannis V, Zhou J, Jorwood NJ, Thomas RJ, Hards DK, Quinn JM, Niforas P, Ng KW, Martin TJ, Gillespie MT. Localization of RANKL (receptor activator of NF kappa B ligand) mRNA and protein in skeletal and extraskelata tissues. *Bone*. 1999;25:525-534.
- Kong YY, Feige U, Sarosi I, Bolon B, Tafuri A, Morony S, Capparelli C, Li J, Elliott R, McCabe S, Wong T, Campagnuolo G, Moran E, Bogoch ER, Van G, Nguyen LT, Ohashi PS, Lacey DL, Fish E, Boyle WJ, Penninger JM. Activated T cell regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. *Nature*. 1999;402:304-313.
- Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, Elliott R, Colombero A, Elliott G, Scully S, Hsu H, Sullivan J, Hawkins N, Davy E, Capparelli C, Eli A, Qian YX, Kaufman S, Sarosi I, Shalhoub V, Senaldi G, Guo J, Delaney J, Boyle WJ. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. *Cell*. 1998;93:165-176.
- Lam J, Nelson CA, Ross FP, Teitelbaum SL, Fremont DH. Crystal structure of the TRANCE/RANKL cytokine reveals determinants of receptor-ligand specificity. *J Clin Invest*. 2001;108:971-979.
- Leibbrandt A and Penninger JM. RANK/RANKL: Regulators of Immune responses and bone physiology. *Ann N Y Acad Sci*. 2008;1143:123-150.
- Loser K, Mehling A, Loeser S, Apelt J, Kuhn A, Grabbe S, Schwarz T, Penninger JM, Beissert S. Epidermal RANKL controls regulatory T-cell numbers via activation of dendritic cells. *Nat Med*. 2006;12:1372-1379.
- Lum L, Wong BR, Josien R, Becherer JD, Erdjument-Bromage H, Schlondorff J, Tempst P, Choi Y, Blobel CP. Evidence for a role of a tumor necrosis factor- α (TNF- α)-converting Enzyme-like protease in shedding of TRANCE, a TNf family member Involved in osteoclastogenesis and dendritic cell survival. *J Biol Chem*. 1999;274:13613-13618.
- Nakashima T, Kobayashi Y, Yamasaki S, Kawakami A, Eguchi K, Sasaki H, Sakai H. Protein expression and functional difference of membrane-bound and soluble receptor activator of NF- κ B ligand: modulation of the expression by osteotropic factors and cytokines. *Biochem Biophys Res Commun*. 2000;275:768-775.
- Rodan GA, Martin TJ. Role of osteoblasts in hormonal control of bone resorption: a hypothesis. *Calcif Tissue Int*. 1981;33:349-351.
- Schett G, Hayer S, Zerina J, Redlich K, Smolen JS. Mechanisms of disease: the link between RANKL and arthritic bone disease. *Nat Clin Pract Rheumatol*. 2005;1:47-54.
- Tsuda E, Goto M, Mochizuki SI, Yano K, Kobayashi F, Morinaga T, Higashio K. Isolation of a novel cytokine from huma fibroblasts that specifically inhibits osteoclastogenesis. *Biochem Biophys Res Commun*. 1997;137-142.
- Wada T, Nakashima T, Hiroshi N, Penninger JM. RANKL-RANK signaling in osteoclastogenesis and bone disease. *Trends Mol Med*. 2006;12:17-25.
- Wong BR, Rho J, Arron J, Robinson E, Orlinick J, Chao M, Kalachikov S, Cayani E, Bartlett FS, Frankel WN, Lee SY, Choi Y. TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells. *J Biol Chem*. 1997;272:25190-25194.
- Wong BR. Et al. TRANCE (tumor necrosis factor -related activation-induced cytokine), a new TNF family member predominantly expressed in T cells, is a dendritic cell-specific survival factor. *J Exp Med*. 1997;186:2075-2080.
- Wong BR, Rho J, Arron J, Robinson E, Orlinick J, Chao M, Kalachikov S, Cayani E, Bartlett FS, Frankel WN, Lee SY, Choi Y. TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal KInase in T cells. *J Biol Chem*. 1997;272:25190-25194.
- Wong BR, Josien R, Lee SY, Vologodskiaia M, Steinman RM, Choi Y. The TRAF family of signal transducers mediates NF- κ B activation by the TRANCE receptor. *J Biol Chem*. 1998;273:28355-28359.
- Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki SI, Tomoyasu A, Yano K, Goto M, Murakami A, Tsuda E, Morinaga T, Higashio K, Udagawa N, Takahashi N, Suda T. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. *Proc Natl Acad Sci USA*. 1998; 95:3597-3602.